Curaleaf Holdings Files 6-K Report

Ticker: CURLF · Form: 6-K · Filed: 2025-11-06T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, corporate-information

TL;DR

Curaleaf filed a 6-K, reporting for Q3 2025, confirming 40-F annual report filing.

AI Summary

Curaleaf Holdings, Inc. filed a Form 6-K on November 6, 2025, reporting for the period ending September 30, 2025. The filing indicates that Curaleaf will file its annual reports under Form 40-F. The company's principal executive office is located in Vancouver, British Columbia, Canada.

Why It Matters

This filing provides an update on Curaleaf's reporting status and corporate information, which is relevant for investors tracking the company's regulatory compliance and financial disclosures.

Risk Assessment

Risk Level: low — This is a routine filing that primarily confirms reporting status and corporate details, with no immediate financial or operational news.

Key Players & Entities

Curaleaf Holdings, Inc. (company) — Registrant
333-249081 (other) — Commission File Number
20250930 (date) — Conformed Period of Report
20251106 (date) — Filed as of Date
Form 40-F (other) — Annual Report Form

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K is to report for the month of November 2025 and to indicate that Curaleaf Holdings, Inc. files its annual reports under Form 40-F.

What period does this filing cover?

This filing is for the conformed period of report ending September 30, 2025.

Where is Curaleaf Holdings, Inc.'s principal executive office located?

Curaleaf Holdings, Inc.'s principal executive office is located at 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8, Canada.

What is the Commission File Number for Curaleaf Holdings, Inc.?

The Commission File Number for Curaleaf Holdings, Inc. is 333-249081.

What is the SIC code for Curaleaf Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Curaleaf Holdings, Inc. is 2833, which corresponds to MEDICINAL CHEMICALS & BOTANICAL PRODUCTS.

From the Filing

0001756770-25-000038.txt : 20251106 0001756770-25-000038.hdr.sgml : 20251106 20251105195004 ACCESSION NUMBER: 0001756770-25-000038 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20250930 FILED AS OF DATE: 20251106 DATE AS OF CHANGE: 20251105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Curaleaf Holdings, Inc. CENTRAL INDEX KEY: 0001756770 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-249081 FILM NUMBER: 251455622 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 781-451-0117 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: LEAD VENTURES INC. DATE OF NAME CHANGE: 20181023 6-K 1 q3256-kcover.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 Commission File Number: 333-249081 Curaleaf Holdings, Inc. (Name of Registrant) 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8, Canada (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐    Form 40-F ☒ INCORPORATION BY REFERENCE Exhibit 99.1 to this Form 6-K of Curaleaf Holdings, Inc. (the “Company”) are hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-269109) of the Company, as amended or supplemented. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CURALEAF HOLDINGS, INC. (Registrant) Date: November 5, 2025 By: /s/ Peter Clateman Name: Peter Clateman Title: Chief Legal Officer EXHIBIT INDEX Exhibit Number Description 99.1 Unaudited Condensed Interim Consolidated Financial Statements as of September 30, 2025 and December 31, 2024 and for the Three and Nine Months Ended September 30, 2025 and 2024 and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 99.2 CEO Certification of Interim Filings 99.3 CFO Certification of Interim Filings 99.4 Press Release dated November 5, 2025 EX-99.1 2 q325-exx992xfsandmda.htm EX-99.1 Document Exhibit 99.2 CURALEAF HOLDINGS, INC. Condensed Interim Consolidated Financial Statements (Unaudited) As of September 30, 2025 and December 31, 2024 and For the Three and Nine Months Ended September 30, 2025 and 2024 (Expressed in Thousands United States Dollars Unless Otherwise Stated) Page(s) Financial Statements: Condensed Interim Consolidated Balance Sheets (Unaudited) as of September 30, 2025 and December 31, 2024 3 Condensed Interim Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2025 and 2024 5 Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) for the three and nine months ended September 30, 2025 and 2024 6 Condensed Interim Consolidated Statements of Temporary Equity and Shareholders’ Equity (Unaudited) for the nine months ended September 30, 2025 and 2024 7 Condensed Interim Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2025 and 2024 8 Notes to Condensed Interim Consolidated Financial Statements (Unaudited) 10 Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months e